Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
5 Biotech Stocks to Bet On Bright Industry Prospects
10:45am, Monday, 29'th Jul 2024
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, S
Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
06:08pm, Wednesday, 24'th Jul 2024
Sarepta Therapeutics, Inc. is a leader in DMD treatment, with recent FDA approval for SRP-9001 gene therapy across all age groups. Despite a recent stock pullback, the company reported strong revenue
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade
10:56am, Friday, 19'th Jul 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable,
3 Biotech Stocks You Should Know About
02:35pm, Wednesday, 17'th Jul 2024
In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now?
01:00pm, Tuesday, 16'th Jul 2024
Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
01:06pm, Monday, 08'th Jul 2024
Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
08:00am, Saturday, 06'th Jul 2024
Sarepta Therapeutics just received expanded labeling for one of its therapies. But the therapy has not performed as well as expected in clinical trials.
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
06:35am, Thursday, 04'th Jul 2024
Previously, Sarepta's gene therapy treatment Elevidys was approved for only a limited number of Duchenne muscular dystrophy patients. Regulators, however, have expanded that range, and it can now be u
Best Momentum Stocks to Buy for July 3rd
11:00am, Wednesday, 03'rd Jul 2024
SRPT and ASYS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 3, 2024.
1 Soaring Growth Stock to Buy and Hold for 10 Years
10:05am, Wednesday, 03'rd Jul 2024
Sarepta Therapeutics' most important medicine now looks even more promising. The biotech's financial results are improving substantially.
New Strong Buy Stocks for July 3rd
07:50am, Wednesday, 03'rd Jul 2024
MONDY, MWA, SRPT, ASYS and CLCO have been added to the Zacks Rank #1 (Strong Buy) List on July 3, 2024.
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
10:06am, Wednesday, 26'th Jun 2024
Pfizer just whiffed one of its late-stage clinical trials. Sarepta Therapeutics just got regulators to sign off on a similar program.
Will Elevidys Approval Make Sarepta Stock An Acquisition Target?
09:00am, Tuesday, 25'th Jun 2024
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, was up 30% on Frid
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
04:50am, Monday, 24'th Jun 2024
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor
Sarepta Therapeutics: Pushing The Edge And Creating The Horizon
06:47am, Saturday, 22'nd Jun 2024
Sarepta Therapeutics excels in rare disease therapies using RNA, gene editing, and gene therapies, with significant revenue growth driven by ELEVIDYS gene therapy approval. Despite missing the primary
